女性乳腺癌的生存特征与趋势:基于癌症登记数据的生存分析综合综述
Survival feature and trend of female breast cancer: A comprehensive review of survival analysis from cancer registration data.
作者信息
Tang Dan-Dan, Ye Zhuo-Jun, Liu Wan-Wan, Wu Jing, Tan Jing-Yu, Zhang Yan, Xu Qun, Xiang Yong-Bing
机构信息
Department of Epidemiology & State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200032, China; School of Public Health, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Health Management Center, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200127, China.
出版信息
Breast. 2025 Feb;79:103862. doi: 10.1016/j.breast.2024.103862. Epub 2024 Dec 15.
To better understand global patterns, chronological changes, and international comparisons of female breast cancer survival, we reviewed published data from population-based cancer registries worldwide. Using PubMed, Embase, Web of Science, SEER, and SinoMed, a comprehensive literature search was conducted for female breast cancer survival from the population-based cancer registries through 31 December 2023. Observed, relative, and net survival rates and their corresponding age-standardized survival rates since the 1990s were collected and further stratified by prognostic factors. The prognosis of female breast cancer patients was favorable, with 5-year relative survival rates above 80 % in most regions. The trend in breast cancer survival showed annual increases in most countries but was accompanied by geographical disparities. The highest age-standardized 5-year relative survival rate was identified in the USA (2010-2014) at 90.2 %, while the lowest was in India (2010-2014) at 66.1 %. Overall, North America and Oceania had the best survival, and, for Europe, survival was worst in Eastern Europe. The survival in some Asian countries was disturbing. Younger age groups had a better prognosis than those aged 75 years and over. The lowest survival rates were observed in patients with distant metastatic and triple-negative breast cancer. Worldwide, there has been a steady improvement in female breast cancer survival. However, the survival gap between developed and developing countries has remained wide over the past 30 years. Differences in age, stage at diagnosis, and molecular subtype may explain some of the disparities, providing evidence for targeted management strategies.
为了更好地了解女性乳腺癌生存的全球模式、时间变化以及国际比较,我们回顾了全球基于人群的癌症登记处发布的数据。通过PubMed、Embase、Web of Science、SEER和中国生物医学文献数据库,对截至2023年12月31日基于人群的癌症登记处中女性乳腺癌生存情况进行了全面的文献检索。收集了自20世纪90年代以来的观察生存率、相对生存率和净生存率及其相应的年龄标准化生存率,并根据预后因素进一步分层。女性乳腺癌患者的预后良好,大多数地区的5年相对生存率超过80%。乳腺癌生存趋势显示,大多数国家呈逐年上升趋势,但存在地域差异。年龄标准化5年相对生存率最高的是美国(2010 - 2014年),为90.2%,最低的是印度(2010 - 2014年),为66.1%。总体而言,北美和大洋洲的生存率最佳,而在欧洲,东欧的生存率最差。一些亚洲国家的生存率令人担忧。年轻年龄组的预后优于75岁及以上年龄组。远处转移和三阴性乳腺癌患者的生存率最低。在全球范围内,女性乳腺癌生存情况一直在稳步改善。然而,在过去30年中,发达国家和发展中国家之间的生存差距仍然很大。年龄、诊断时的分期和分子亚型的差异可能解释了部分差距,为针对性管理策略提供了证据。